The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies

Psoriatic Arthritis

Serum CRP, IL-17A, and IL-17F levels are responsive to ustekinumab in psoriatic arthritis: lessons from the PSUMMIT study programme

Arthritis Rheumatol.

Siebert S, Sweet K, Dasgupta B, Campbell K, McInnes IB, Loza MJ

doi: 10.1002/art.40921.

Psoriatic ArthritisRheumatoid Arthritis

Persistence with golimumab in immune-mediated rheumatic diseases: a systematic review of real-world evidence in rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis

Patient Prefer Adherence.

Svedbom A, Storck C, Kachroo S, Govoni M, Khalifa A

doi: 10.2147/PPA.S128665.

Rheumatoid ArthritisSpinal Disorders

Serum calprotectin: a promising biomarker in rheumatoid arthritis and axial spondyloarthritis

Arthritis Res Ther.

Jarlborg M, Courvoisier DS, Lamacchia C, Martinez Prat L, Mahler M, Bentow C, Finckh A, Gabay C, Nissen MJ, physicians of the Swiss Clinical Quality Management (SCQM) registry.

doi: 10.1186/s13075-020-02190-3.

Psoriatic ArthritisRheumatoid Arthritis

Dual inhibition of tumour necrosis factor and interleukin-17A with ABT-122: open-label long-term extension studies in rheumatoid arthritis or psoriatic arthritis

Rheumatology (Oxford).

Genovese MC, Weinblatt ME, Mease PJ, Aelion JA, Peloso PM, Chen K, Li Y, Liu J, Othman AA, Khatri A, Mansikka HT, Leszczynski P

doi: 10.1093/

COMMENTED

Spinal Disorders

Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial

Lancet.

van der Heijde D, Cheng-Chung Wei J, Dougados M, Mease P, Deodhar A, Maksymowych WP, Van den Bosch F, Sieper J, Tomita T, Landewé R, Zhao F, Krishnan E, Adams DH, Pangallo B, Carlier H; COAST-V study group

doi: 10.1016/S0140-

Psoriatic Arthritis

Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis

Ann Rheum Dis.

Kerschbaumer A, Smolen JS, Dougados M, de Wit M, Primdahl J, McInnes I, van der Heijde D, Baraliakos X, Falzon L, Gossec L

doi: 10.1136/annrheumdis-2020-217163.

Further Publications Rheumatology

Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial

Ann Rheum Dis

Baraliakos X, Gossec L, Pournara E, Jeka S, Mera-Varela A, D'Angelo S, Schulz B, Rissler M, Nagar K, Perella C, Coates LC

doi: 10.1136/annrheumdis-2020-218808

Psoriatic Arthritis

Editorial: Sacroiliac Joint Magnetic Resonance Imaging in the Diagnosis of Axial Spondyloarthritis: “A Tiny Bit of White on Two Consecutive Slices” May Be Objective, but Not Specific

Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 2015;373:2247-2257 Full Text | Web of Science | Medline

Rheumatoid Arthritis

Exposure-response analyses demonstrate no evidence of interleukin 17A contribution to efficacy of ABT-122 in rheumatoid or psoriatic arthritis

Rheumatology (Oxford).

Khatri A, Klünder B, Peloso PM, Othman AA

doi: 10.1093/rheumatolog/key312.

Related content

Serum CRP, IL-17A, and IL-17F levels are responsive to ustekinumab in psoriatic arthritis: lessons from the PSUMMIT study programme

Persistence with golimumab in immune-mediated rheumatic diseases: a systematic review of real-world evidence in rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis

Serum calprotectin: a promising biomarker in rheumatoid arthritis and axial spondyloarthritis

Dual inhibition of tumour necrosis factor and interleukin-17A with ABT-122: open-label long-term extension studies in rheumatoid arthritis or psoriatic arthritis

Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis

Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial

Editorial: Sacroiliac Joint Magnetic Resonance Imaging in the Diagnosis of Axial Spondyloarthritis: “A Tiny Bit of White on Two Consecutive Slices” May Be Objective, but Not Specific

Exposure-response analyses demonstrate no evidence of interleukin 17A contribution to efficacy of ABT-122 in rheumatoid or psoriatic arthritis